Zobrazeno 1 - 10
of 433
pro vyhledávání: '"Minxia, M."'
Autor:
Wirth, David D *, He, Minxia M, Czeskis, Boris A, Zimmerman, Karen M, Roettig, Ulrike, Stenzel, Wolfgang, Steinberg, Mitchell I
Publikováno v:
In European Journal of Medicinal Chemistry 2002 37(1):23-34
Autor:
He, Minxia M.1 (AUTHOR) he_michelle_minxia@lilly.com, Ji, Tao1 (AUTHOR) he_michelle_minxia@lilly.com, Barbuch, Robert J.1,2 (AUTHOR), Campanale, Kristina1 (AUTHOR), Lantz, Ron1 (AUTHOR), Hadden, Chad3 (AUTHOR), Wilke, August4 (AUTHOR)
Publikováno v:
Xenobiotica. Dec2011, Vol. 41 Issue 12, p1108-1121. 14p.
Publikováno v:
British Journal of Clinical Pharmacology. 73:268-284
AIM The most common causes of variability in drug response include differences in drug metabolism, especially when the hepatic cytochrome P450 (CYP) enzymes are involved. The current study was conducted to assess the differences in CYP activities in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::334452592b3673f18439c2d0783890ed
https://doi.org/10.1111/j.1365-2125.2011.04076.x
https://doi.org/10.1111/j.1365-2125.2011.04076.x
Publikováno v:
Xenobiotica. 35:647-660
The metabolism and disposition of LY 368842, a beta 3-adrenergic receptor agonist, were characterized in F344 rats following oral or intravenous administration of [(14)C]LY 368842. These studies were conducted as part of the investigation of the mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30cbf1ffded9ffba7a1f03f5200314c
https://doi.org/10.1080/00498250500187992
https://doi.org/10.1080/00498250500187992
Autor:
Shawn Flanagan, Clark Chan, Eyas Abu-Raddad, Hikari Watanabe, Danny Soon, Stephen D. Wise, Akira Sasaki, Kwee Poo Yeo, Vikram Sinha, Georg Golor, Minxia M. He
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:1813-1822
Alamifovir, a purine nucleotide analogue prodrug, and its hydrolyzed derivatives have shown preclincal efficacy activity against wild-type and lamivudine-resistant hepatitis B virus. Two studies were conducted to examine the single- and multiple-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9caa0802494cca7a1cfee16aea66938
https://doi.org/10.1128/aac.49.5.1813-1822.2005
https://doi.org/10.1128/aac.49.5.1813-1822.2005
Autor:
Hans C. Schaefer, Stuart D. Oliver, Isabelle J. Pouliquen, Christopher D. Payne, Malcolm I. Mitchell, Thomas J. Lindsay, Trent L. Abraham, Minxia M. He, Lisa A. Shipley, Boris A. Czeskis
Publikováno v:
Drug Metabolism and Disposition. 31:334-342
The metabolism and pharmacokinetics of moxonidine, a potent central-acting antihypertensive agent, were studied in four healthy subjects after a single oral administration of approximately 1 mg (approximately 60 muCi) of [(14)C(3)]moxonidine. Moxonid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b2fcf711849a38c8be46af01d81493
https://doi.org/10.1124/dmd.31.3.334
https://doi.org/10.1124/dmd.31.3.334
Autor:
Minxia M. He, Hans Guenter Schaefer, Clark Chan, Stephen D. Wise, Isabelle J. Pouliquen, Malcolm I. Mitchell
Publikováno v:
British Journal of Clinical Pharmacology. 54:251-254
Aims To test the hypothesis that the renal clearance of moxonidine decreases when dosed with quinidine. Methods A randomized, two-period study was conducted with six healthy, male subjects orally dosed with either 0.2 mg moxonidine alone or 1 h after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::288f4092fbfa1f84093191bf1f845aa6
https://doi.org/10.1046/j.1365-2125.2002.01647.x
https://doi.org/10.1046/j.1365-2125.2002.01647.x
Autor:
Chad E. Hadden, Robert J. Barbuch, Ron Lantz, August Wilke, Tao Ji, Minxia M. He, Kristina M. Campanale
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 41(12)
LY377604 has a potential to form 4-hydroxycarbazole, which was reported in the literature as a mutagen. This safety concern led to our investigation of the metabolism and carcinogenicity of LY377604. In in vitro studies with LY377604, 4-hydroxycarbaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54779d490b153b92928b0dc744912207
https://pubmed.ncbi.nlm.nih.gov/21892880
https://pubmed.ncbi.nlm.nih.gov/21892880
Publikováno v:
British journal of clinical pharmacology. 73(2)
The most common causes of variability in drug response include differences in drug metabolism, especially when the hepatic cytochrome P450 (CYP) enzymes are involved. The current study was conducted to assess the differences in CYP activities in huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::37f7cea7507dc9b5f7fce266f43ffa2a
https://pubmed.ncbi.nlm.nih.gov/21815912
https://pubmed.ncbi.nlm.nih.gov/21815912
Autor:
Cynthia Darshini Jesudason, Christopher John Rito, James E. Baker, Aidas Kriauciunas, Minxia M. He, William G. Trankle, Robert D. Bryant, Frank C. Tinsley, Gregory A Gaich, Julie Satterwhite, Steven D. Kahl, Anthony J. Shuker, Libbey S. O’Farrell, Mary A. Peters, Fisher Jack Wayne, Mark L. Heiman
We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799540a006049b90706c7577cf79b371
https://europepmc.org/articles/PMC4018109/
https://europepmc.org/articles/PMC4018109/
